Companies

Unichem Labs gets USFDA nod for plaque psoriasis drug

New Delhi | Updated on February 19, 2021 Published on February 19, 2021

Apremilast tablets are used to treat adult patients with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy

Drug firm Unichem Laboratories on Friday said it has received approval from the US health regulator to market Apremilast tablets, used for treatment of plaque psoriasis.

Apremilast tablets are indicated for the treatment of adult patients with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy.

Also read: Sun Pharma gains 2% on launching psoriasis drug in Japan

The company has received abbreviated new drug application (ANDA) approval to market its Apremilast tablets in the strengths of 10 mg, 20 mg and 30 mg from the United States Food and Drug Administration (USFDA), Unichem Labs said in a regulatory filing.

The approved product is a generic version of Amgen's Otezla tablets.

Shares of Unichem Labs were trading 1.36 per cent higher at ₹309.75 apiece on the BSE.

Follow us on Telegram, Facebook, Twitter, Instagram, YouTube and Linkedin. You can also download our Android App or IOS App.

Published on February 19, 2021
  1. Comments will be moderated by The Hindu Business Line editorial team.
  2. Comments that are abusive, personal, incendiary or irrelevant cannot be published.
  3. Please write complete sentences. Do not type comments in all capital letters, or in all lower case letters, or using abbreviated text. (example: u cannot substitute for you, d is not 'the', n is not 'and').
  4. We may remove hyperlinks within comments.
  5. Please use a genuine email ID and provide your name, to avoid rejection.